KEY INFO

Investment Summary
e-therapeutics is a UK biotech using its proprietary computational biology and RNAi chemistry pETX’s HepNet platform is a well-established AI-driven drug discovery platform that gets new drugs to market faster, cheaper and with an increased probability of successful outcomes. It’s the type of strategic asset that is likely to interest numerous big pharma companies in future.latforms to identify novel gene targets and rapidly develop RNAi therapies.
Investor Relations

FREQUENTLY ASKED QUESTIONS

Why should investors care about ETX?

e-therapeutics offers the opportunity to invest in a competent team that is delivering a promising future modality, underpinned by a proven business model and supported by Artifical Intelligence across the entire value chain. e-therapeutics can deliver a drug from concept to proof-of-concept within a year, for just £1m versus typical industry cost of at least £5-10m.

What challenges is ETX facing?

Firstly, geopolitical issues worldwide have put pressure on delivery timelines and pricing, due to the increase in costs of raw matierals globally.

Secondly, Bio-technology sector is undergoing a correction leading to more cautious behaviour by potential partners and investors in the near-term.

Have you validated your computational platform?

Yes, e-therapeutics' computational platform has successfully identified gene-disease pairs and has subsequently shown signifcant positive data to prove safety and efficacy of those drugs.

How does ETX plan to finance future clinical trials?

The future trajectory involves partnership deals across the various pre-clinical and clinical stages for individual therapeutic canidates, which can help to mitigate the need to raise dilutive capital.

MEDIA

COMPANY INFO

KEY SOCIALS & INFLUENCERS

COMPANY RESEARCH

ARTICLES

e-therapeutics business update and news regarding pre-clinical drug candidates
Biotechs are applying AI and machine learning to speed up drug development
Novartis snaps up rare disease biotech DTx Pharma in $1bn deal

The acquisition adds an siRNA delivery platform to Novartis’s armament and a potential first-in-class treatment for Charcot-Marie-Tooth Disease.

The Next Frontier For Large Language Models Is Biology

Large language models like GPT-4 have taken the world by storm thanks to their astonishing command of natural language. Yet the most significant long-term opportunity for LLMs will entail an entirely different type of language: the language of biology.

M&G invests in UK-based innovator e-therapeutics

M&G Investments has provided a further £13.5 million of funding and an increased shareholding in e-therapeutics, a UK-based innovator in computer technology for the development of life-transforming medicines.

20th Anniversary of RNA Interference in Mammalian Cells

The groundbreaking discovery of RNA interference by Craig Mello and Andrew Fire was swiftly followed by the discovery of RNAi as a gene-silencing mechanism in mammalian cells.

e-therapeutics tie-up will use big data to identify new treatments
Novo Nordisk Snaps Up Partner Dicerna for $3.3 Billion